Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidylprolyl isomerase A pseudogene 59 (PPIAP59) is classified as a human pseudogene with close sequence similarity to the protein-coding PPIA gene, which encodes cyclophilin A, an enzyme involved in protein folding, signal transduction, and immune response[1][6][7]. Unlike PPIA, PPIAP59 does not produce a functional protein and is not implicated in any characterized biological processes, drug interactions, or direct disease roles[10][2]. Pseudogenes such as PPIAP59 may have residual or regulatory roles at the RNA level (as non-coding RNAs), but current data provide no evidence for biological activity, disease relevance, or utility as a therapeutic target for PPIAP59[11]. If a functional or druggable target is desired, the focus should be on peptidylprolyl isomerase A (PPIA) rather than its pseudogene PPIAP59[1][10][2].
None applicable — Inactive as a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidylprolyl isomerase A pseudogene 59 (PPIAP59).